Glenmark Pharma receives ANDA approval ; stock trades positive

Glenmark Phamaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Tretinoin Capsules, 10 mg, the generic version of Vesanoid Capsules, 10 mg, of Hoffmann La Roche, Inc., (which is no longer being marketed in the United States). 

According to IMS Health's sales data for the 12 month period ending October 2016, the Vesanoid Capsules, 10 mg market1 has achieved annual sales of approximately $22.0 million.

Glenmark’s current portfolio consists of 112 products authorised for distribution in the U.S. marketplace and 63 ANDAs pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. 

Glenmark Pharmaceuticals Ltd., (GPL) is a research‐driven, global, integrated pharmaceutical organisation headquartered at Mumbai, India.

Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.] and Pain [neuropathic pain and inflammatory pain]. 
The company has a significant presence in the branded generics' markets across emerging economies including India.

The stock is trading at Rs 893 per share on Tuesday, up by Rs 4.55 per share or 0.51 per cent on an intraday basis. Over a one year period the stock has delivered negative 3.3 per cent.